We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FTAL:TASEFattal Holdings (1998) Ltd. Analysis

Data as of 2026-03-16 - not real-time

ILA 59,940.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

FTAL is trading at 59,940 ILA, barely above its 20‑day SMA of 62,534 and well below the 50‑day SMA of 64,791, indicating weak momentum. The 14‑day RSI of 37 suggests the stock is approaching oversold territory. MACD remains bearish, with the line sitting below the signal and a negative histogram. Support sits near 59,060 while resistance is around 66,970, framing a narrow upside corridor. Volume is increasing despite modest absolute numbers, hinting at growing participant interest. However, the fear‑greed index reads 72.9 (Greed), implying market optimism that may be disconnected from fundamentals.
Fundamentally, FTAL carries an astronomically high PE of 555 and a PB of 217, signaling extreme overvaluation. Revenue growth is modest at 5% and profit margins are razor‑thin (0.2% net), while ROE languishes at 0.4%. The balance sheet is heavily leveraged with a debt‑to‑equity of over 500 and negative free cash flow, raising solvency concerns. Beta is low at 0.18, but 30‑day volatility is high at 27.6%, reflecting price instability. The lodging sector is highly cyclical, and the company’s exposure to Israel adds geopolitical risk. Given these dynamics, the stock appears overvalued with limited upside, suggesting a cautious stance.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • price near support level
  • bearish MACD
  • high valuation metrics

Medium Term

1–3 years
Cautious
Model confidence: 7/10

Key Factors

  • excessive debt load
  • negative free cash flow
  • persistent overvaluation

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • low profitability and ROE
  • cyclical lodging exposure
  • geopolitical risk in primary market

Key Metrics & Analysis

Financial Health

Revenue Growth5.00%
Profit Margin0.23%
P/E Ratio555.0
ROE0.42%
ROA1.91%
Debt/Equity501.45
P/B Ratio217.0
Op. Cash FlowILA950.4M
Free Cash FlowILA-946648256

Technical Analysis

TrendNeutral
RSI37.6
SupportILA 59,060.00
ResistanceILA 66,970.00
MA 20ILA 62,534.50
MA 50ILA 64,791.00
MA 200ILA 58,267.40
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

GradeOvervalued
TypeValue

Risk Assessment

Beta0.18
Volatility27.59%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.